Intranasal immunization protects against Acinetobacter baumannii-associated pneumonia in mice

Vaccine

Volumn 33, Issue 1, 2015, Pages 260-267

  KuoLee, Rhonda ^a   Harris, Greg ^a   Yan, Hongbin ^b   Xu, H Howard ^c   Conlan, Wayne J ^a   Patel, Girishchandra B ^a   Chen, Wangxue ^a,b  

^a NATIONAL RESEARCH COUNCIL CANADA   (Canada)

^b BROCK UNIVERSITY   (Canada)

^c CALIFORNIA STATE UNIVERSITY   (United States)

Author keywords

Acinetobacter baumannii; B cells; Mice; Mucosal immunization; Neutrophils; Pneumonia

Indexed keywords

ACINETOBACTER BAUMANNII VACCINE; BACTERIAL VACCINE; CHEMOATTRACTANT; FC RECEPTOR; FC RECEPTOR GAMMA; IMMUNOGLOBULIN A ANTIBODY; IMMUNOGLOBULIN G1 ANTIBODY; IMMUNOGLOBULIN G2A ANTIBODY; INTERLEUKIN 1BETA; INTERLEUKIN 6; KERATINOCYTE CHEMOATTRACTANT; MACROPHAGE INFLAMMATORY PROTEIN 2; MONOCYTE CHEMOTACTIC PROTEIN 1; RANTES; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ACINETOBACTER BAUMANNII; ACINETOBACTER INFECTION; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY RESPONSE; ANTIGEN SPECIFICITY; ARTICLE; B LYMPHOCYTE; BACTERIAL STRAIN; BACTERIUM DETECTION; BACTERIUM ISOLATE; BLOOD SAMPLING; CELL SURVIVAL; CONTROLLED STUDY; CYTOKINE RESPONSE; FEMALE; HISTOPATHOLOGY; IMMUNE RESPONSE; IMMUNIZATION; INFECTION PREVENTION; INFLAMMATION; LIMIT OF DETECTION; LUNG; MORTALITY; MOUSE; MUCOSAL IMMUNITY; NEUTROPENIA; NEUTROPHIL; NONHUMAN; PASSIVE IMMUNIZATION; PNEUMONIA; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; SPLEEN; SURVIVAL TIME; ACINETOBACTER INFECTIONS; ANIMAL; BACTERIAL LOAD; BAGG ALBINO MOUSE; BLOOD; C57BL MOUSE; DISEASE MODEL; HUMAN; IMMUNOLOGY; INTRANASAL DRUG ADMINISTRATION; MALE; MICROBIOLOGY; PATHOLOGY; PNEUMONIA, BACTERIAL; PROCEDURES; SURVIVAL;

ACINETOBACTER BAUMANNII; ACINETOBACTER INFECTIONS; ADMINISTRATION, INTRANASAL; ANIMALS; B-LYMPHOCYTES; BACTERIAL LOAD; BACTERIAL VACCINES; BLOOD; DISEASE MODELS, ANIMAL; FEMALE; HUMANS; IMMUNIZATION; IMMUNIZATION, PASSIVE; LUNG; MALE; MICE, INBRED BALB C; MICE, INBRED C57BL; NEUTROPHILS; PNEUMONIA, BACTERIAL; SPLEEN; SURVIVAL ANALYSIS;

EID: 84919460368     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2014.02.083     Document Type: Article

References (32)

1. Hartzell J.D., Kim A.S., Kortepeter M.G., Moran K.A. Acinetobacter pneumonia: a review. MedGenMed 2007, 9:4.
2. Kuo L.C., Lai C.C., Liao C.H., Hsu C.K., Chang Y.L., Chang C.Y., et al. Multidrug-resistant Acinetobacter baumannii bacteraemia: clinical features, antimicrobial therapy and outcome. Clin Microbiol Infect 2007, 13:196-198.
3. Vila J., Pachon J. Therapeutic options for Acinetobacter baumannii infections. Expert Opin Pharmacother 2008, 9:587-599.
4. Fournier P.E., Richet H. The epidemiology and control of Acinetobacter baumannii in health care facilities. Clin Infect Dis 2006, 42:692-699.
5. Abbo A., Carmeli Y., Navon-Venezia S., Siegman-Igra Y., Schwaber M.J. Impact of multi-drug-resistant Acinetobacter baumannii on clinical outcomes. Eur J Clin Microbiol Infect Dis 2007, 26:793-800.
6. Valencia R., Arroyo L.A., Conde M., Aldana J.M., Torres M.J., Fernandez-Cuenca F., et al. Nosocomial outbreak of infection with pan-drug-resistant Acinetobacter baumannii in a tertiary care university hospital. Infect Control Hosp Epidemiol 2009, 30:257-263.
7. Taccone F.S., Rodriguez-Villalobos H., De Backer D., De Moor V., Deviere J., Vincent J.L., et al. Successful treatment of septic shock due to pan-resistant Acinetobacter baumannii using combined antimicrobial therapy including tigecycline. Eur J Clin Microbiol Infect Dis 2006, 25:257-260.
8. McConnell M.J., Actis L., Pachon J. Acinetobacter baumannii: human infections, factors contributing to pathogenesis and animal models. FEMS Microbiol Rev 2012, [Epub ahead of print]. 10.1111/j.1574-6976.2012.00344.x.
9. Garcia-Quintanilla M., Pulido M.R., Lopez-Rojas R., Pachon J., McConnell M.J. Emerging therapies for multidrug resistant Acinetobacter baumannii. Trends Microbiol 2013, 21:157-163.
10. Bentancor L.V., Routray A., Bozkurt-Guzel C., Camacho-Peiro A., Pier G.B., Maira-Litran T. Evaluation of the trimeric autotransporter Ata as a vaccine candidate against Acinetobacter baumannii infections. Infect Immun 2012, 80:3381-3388.
11. Luo G., Lin L., Ibrahim A.S., Baquir B., Pantapalangkoor P., Bonomo R.A., et al. Active and passive immunization protects against lethal, extreme drug resistant-Acinetobacter baumannii infection. PLoS ONE 2012, 7:e29446.
12. McConnell M.J., Pachon J. Active and passive immunization against Acinetobacter baumannii using an inactivated whole cell vaccine. Vaccine 2010, 29:1-5.
13. Fattahian Y., Rasooli I., Mousavi Gargari S.L., Rahbar M.R., Darvish Alipour Astaneh S., Amani J. Protection against Acinetobacter baumannii infection via its functional deprivation of biofilm associated protein (Bap). Microb Pathog 2011, 51:402-406.
14. Russo T.A., Luke N.R., Beanan J.M., Olson R., Sauberan S.L., MacDonald U., et al. The K1 capsular polysaccharide of Acinetobacter baumannii strain 307-0294 is a major virulence factor. Infect Immun 2010, 78:3993-4000.
15. Bentancor L.V., O'Malley J.M., Bozkurt-Guzel C., Pier G.B., Maira-Litran T. Poly-N-acetyl-beta-(1-6)-glucosamine is a target for protective immunity against Acinetobacter baumannii infections. Infect Immun 2012, 80:651-656.
16. McConnell M.J., Dominguez-Herrera J., Smani Y., Lopez-Rojas R., Docobo-Perez F., Pachon J. Vaccination with outer membrane complexes elicits rapid protective immunity to multidrug-resistant Acinetobacter baumannii. Infect Immun 2011, 79:518-526.
17. Lin L., Tan B., Pantapalangkoor P., Ho T., Hujer A.M., Taracila M.A., et al. Acinetobacter baumannii rOmpA vaccine dose alters immune polarization and immunodominant epitopes. Vaccine 2013, 31:313-318.
18. Harris G., KuoLee R., Lam C.K., Kanzaki G., Patel G.B., Xu H.H., et al. A mouse model of Acinetobacter baumannii-associated pneumonia using a clinically isolated hypervirulent strain. Antimicrob Agents Chemother 2013, 57:3601-3613.
19. van Faassen H., KuoLee R., Harris G., Zhao X., Conlan J.W., Chen W. Neutrophils play an important role in host resistance to respiratory infection with Acinetobacter baumannii in mice. Infect Immun 2007, 75:5597-5608.
20. Chen W., Havell E.A., Moldawer L.L., McIntyre K.W., Chizzonite R.A., Harmsen A.G. Interleukin 1: an important mediator of host resistance against Pneumocystis carinii. J Exp Med 1992, 176:713-718.
21. Yan H., KuoLee R., Tram K., Qiu H., Zhang J., Patel G.B., et al. 3',5'-Cyclic diguanylic acid elicits mucosal immunity against bacterial infection. Biochem Biophys Res Commun 2009, 387:581-584.
22. KuoLee R., Harris G., Conlan J.W., Chen W. Role of neutrophils and NADPH phagocyte oxidase in host defense against respiratory infection with virulent Francisella tularensis in mice. Microbes Infect 2011, 13:447-456.
23. Marks M., Burns T., Abadi M., Seyoum B., Thornton J., Tuomanen E., et al. Influence of neutropenia on the course of serotype 8 pneumococcal pneumonia in mice. Infect Immun 2007, 75:1586-1597.
24. Patel G.B., Zhou H., Ponce A., Harris G., Chen W. Intranasal immunization with an archaeal lipid mucosal vaccine adjuvant and delivery formulation protects against a respiratory pathogen challenge. PLoS ONE 2010, 5:e15574.
25. Shen H., Harris G., Chen W., Sjostedt A., Ryden P., Conlan J.W. Molecular immune responses to aerosol challenge with francisella tularensis in mice inoculated with live vaccine candidates of varying efficacy. PLoS ONE 2010, 5:e13349.
26. Gao X.P., Standiford T.J., Rahman A., Newstead M., Holland S.M., Dinauer M.C., et al. Role of NADPH oxidase in the mechanism of lung neutrophil sequestration and microvessel injury induced by Gram-negative sepsis: studies in p47phox-/- and gp91phox-/- mice. J Immunol 2002, 168:3974-3982.
27. Mastroeni P., Vazquez-Torres A., Fang F.C., Xu Y., Hormaeche C.E., et al. Antimicrobial actions of the NADPH phagocyte oxidase and inducible nitric oxide synthase in experimental salmonellosis. II. Effects on microbial proliferation and host survival in vivo. J Exp Med 2000, 192:237-248.
28. Takai T. Multiple loss of effector cell functions in FcR gamma-deficient mice. Int Rev Immunol 1996, 13:369-381.
29. Chen W., Shen H., Webb A., KuoLee R., Conlan J.W. Tularemia in BALB/c and C57BL/6 mice vaccinated with Francisella tularensis LVS and challenged intradermally, or by aerosol with virulent isolates of the pathogen: protection varies depending on pathogen virulence, route of exposure, and host genetic background. Vaccine 2003, 21:3690-3700.
30. North R.J., LaCourse R., Ryan L. Vaccinated mice remain more susceptible to Mycobacterium tuberculosis infection initiated via the respiratory route than via the intravenous route. Infect Immun 1999, 67:2010-2012.
31. Ketter P., Guentzel M., Gupta R., Yu J.-J., Chambers J., Arulanandam B. SIgA enhances Acinetobacter baumannii gastrointestinal colonization. 16th international congress of mucosal immunology 2013, 111.
32. Breslow J.M., Meissler J.J., Hartzell R.R., Spence P.B., Truant A., Gaughan J., et al. Innate immune responses to systemic Acinetobacter baumannii infection in mice: neutrophils, but not interleukin-17, mediate host resistance. Infect Immun 2011, 79:3317-3327.